Latest filing published 14 Sept 2026 for Jazz Pharmaceuticals plc, €248k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Neena M. Patil (senior executive) discloses dealings in 2 companies, chiefly Jazz Pharmaceuticals plc and Teleflex Inc. Over a trading history stretching from 5 August 2021 to 10 September 2026, the count stands at 27 filings.
No open-market purchase appears, only 9 sales worth €2.7M. The rest of the record consists of 14 share grants and 1 option exercise. In 2026 alone, the filings show no purchases and 1 sale.
The latest filing, published on 14 September 2026, reports an open-market sale of €248k in Jazz Pharmaceuticals plc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 27 declarations